Correlation between adenovirus-neutralizing antibody titer and adenovirus vector-mediated transduction efficiency following intratumoral injection

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1145-1152

  Tomita, Kyoko ^a   Sakurai, Fuminori ^a   Tachibana, Masashi ^a   Mizuguchi, Hiroyuki ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Adenovirus vector; Anti adenovirus neutralizing antibody; Gene therapy; Intratumoral administration

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL EVALUATION; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; GENE DOSAGE; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; TRANSDUCTION, GENETIC;

EID: 84859987708     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Benihoud K, Yeh P and Perricaudet M: Adenovirus vectors for gene delivery. Curr Opin Biotech 10: 440-447, 1999. (Pubitemid 29457268)
2. Kovesdi I, Brough DE, Bruder JT and Wickham TJ: Adenoviral vectors for gene transfer. Curr Opin Biotech 8: 583-589, 1997. (Pubitemid 27455335)
3. Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN and Barouch DH: Adenovirus Serotype 5 Neutralizing Antibodies Target both Hexon and Fiber following Vaccination and Natural Infection. Journal of Virology 86: 625-629, 2012.
4. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J and Barouch DH: Hexonchimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243, 2006.
5. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J and Havenga M: Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. Journal of Virology 77: 8263-8271, 2003. (Pubitemid 36871454)
6. Zaiss AK, Machado HB and Herschman HR: The Influence of Innate and Pre-Existing Immunity on Adenovirus Therapy. J Cell Biochem 108: 778-790, 2009.
7. De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW, Slaterus KW, Wertheim-Van Dillen P, Van Doornum GJJ, Khoo SH and Hierholzer JC: Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 37: 3940-3945, 1999.
8. Jones MS, Harrach B, Ganac RD, Gozum MMA, dela Cruz WP, Riedel B, Pan C, Delwart EL and Schnurr DP: New adenovirus species found in a patient presenting with gastroenteritis. Journal of Virology 81: 5978-5984, 2007. (Pubitemid 46847034)
9. Walsh MP, Seto J, Liu EB, Dehghan S, Hudson NR, Lukashev AN, Ivanova O, Chodosh J, Dyer DW, Jones MS and Seto D: Computational Analysis of Two Species C Human Adenoviruses Provides Evidence of a Novel Virus. J Clin Microbiol 49: 3482-3490, 2011.
10. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG and Goudsmit J: International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29: 5203-5209, 2011.
11. Parker AL, Waddington SN, Buckley SMK, Custers J, Havenga MJE, van Rooijen N, Goudsmit J, Mcvey JH, Nicklin SA and Baker AH: Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer. Journal of Virology 83: 479-483, 2009.
12. Pilankatta R, Chawla T, Khanna N and Swaminathan S: The Prevalence of Antibodies to Adenovirus Serotype 5 in an Adult Indian Population and Implications for Adenovirus Vector Vaccines. J Med Virol 82: 407-414, 2010.
13. Sun CJ, Zhang YF, Feng LQ, Pan WQ, Zhang MC, Hong ZY, Ma X, Chen XP and Chen L: Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine 29: 3837-3841, 2011.
14. Liu TC, Galanis E and Kirn D: Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117, 2007. (Pubitemid 46189539)
15. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S and Kirn D: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 60: 6359-6366, 2000.
16. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J and Roth J: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18: 609-622, 2000. (Pubitemid 30078542)
17. Bramson JL, Hitt M, Gauldie J and Graham FL: Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 4: 1069-1076, 1997. (Pubitemid 27469937)
18. Chen P, Kovesdi I and Bruder TJ: Effective repeat administration with adenovirus vectors to the muscle. Gene Ther 7: 587-595, 2000. (Pubitemid 30175562)
19. Li Z, Rakkar A, Katayose Y, Kim M, Shanmugam N, Srivastava S, Moul JW, McLeod DG, Cowan KH and Seth P: Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. Gene Ther 5: 605-613, 1998. (Pubitemid 28256810)
20. Tsai V, Johnson DE, Rahman A, Wen SF, LaFace D, Philopena J, Nery J, Zepeda M, Maneval DC, Demers GW and Ralston R: Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 10: 7199-7206, 2004. (Pubitemid 39487706)
21. Vlachaki MT, Hernandez-Garcia A, Ittmann M, Chhikara M, Aguilar LK, Zhu XH, The BS, Butler EB, Woo S, Thompson TC, Barrera-Saldana H and Aguilar-Cordova E: Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther 6: 342-348, 2002. (Pubitemid 36305336)
22. Varnavski AN, Calcedo R, Bove M, Gao G and Wilson JM: Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and preimmunized mice. Gene Ther 12: 427-436, 2005. (Pubitemid 40394295)
23. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA and Hayakawa T: A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the Hl loop of their fiber knob. Gene Ther 8: 730-735, 2001. (Pubitemid 32496435)
24. Koizumi N, Mizuguchi H, Utoguchi N, Watanabe Y and Hayakawa T: Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J Gene Med 5: 267-276, 2003. (Pubitemid 40310379)
25. Maizel JV, White DO and Scharff MD: Polypeptides of Adenovirus .I. Evidence for Multiple Protein Components in Virion and a Comparison of Types 2 7a and 12. Virology 36: 115-&, 1968.
26. Mizuguchi H and Hayakawa T: Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther 9: 236-242, 2002. (Pubitemid 34205497)
27. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, Goudsmit J, Havenga MJE and Kostense S: Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41: 5046-5052, 2003. (Pubitemid 37429914)
28. Koizumi N, Kawabata K, Sakurai F, Watanabe Y, Hayakawa T and Mizuguchi H: Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alpha(v) integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 17: 264-279, 2006.
29. Suzuki T, Sakurai F, Nakamura S, Kouyama E, Kawabata K, Kondoh M, Yagi K and Mizuguchi H: miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther 16: 1719-1726, 2008.
30. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL and Goudsmit J: Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172: 6290-6297, 2004. (Pubitemid 38621236)
31. Gao JQ, Eto Y, Yoshioka Y, Sekiguchi F, Kurachi S, Morishige T, Yao X, Watanabe H, Asavatanabodee R, Sakurai F, Mizuguchi H, Okada Y, Mukai Y, Tsutsumi Y, Mayumi T, Okada N and Nakagawa S: Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release 122: 102-110, 2007. (Pubitemid 47284554)
32. Iguchi K, Sakurai F, Tomita K, Katayama K, Yamaguchi T, Kawabata K, Tagawa M, Kawabata M, Shirakawa T and Mizuguchi H: Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells. Cancer Gene Ther, 2011.
33. Sakurai F, Mizuguchi H and Hayakawa T: Efficient gene transfer into human CD34(+) cells by an adenovirus type 35 vector. Gene Ther 10: 1041-1048, 2003. (Pubitemid 36722495)
34. Suzuki-Kouyama E, Katayama K, Sakurai F, Yamaguchi T, Kurachi S, Kawabata K, Nakagawa S and Mizuguchi H: Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction. Biomaterials 32: 1724-1730, 2011.
35. Tao NJ, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J and Fawell SE: Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 3: 28-35, 2001. (Pubitemid 32509802)